Transcriptomics

Dataset Information

0

Transcriptional effects of CTGF inhibition and gemcitabine in the KPC mouse model of pancreatic ductal adenocarcinoma


ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) is characterized by abundant desmoplasia and poor tissue perfusion. These features are proposed to limit access of therapies to neoplastic cells and blunt treatment efficacy. Indeed, several agents that target the PDA microenvironment promote chemotherapy delivery and improve anti-neoplastic responses in murine models of PDA. Here, we employed the FG-3019 monoclonal antibody directed against the pleiotropic matricellular signaling molecule connective tissue growth factor (CTGF/CCN2). FG-3019 treatment increased PDA cell killing and led to a dramatic tumor response without altering gemcitabine delivery. Microarray expression profiling revealed the down-regulation by FG-3019 of several anti-apoptotic transcripts, including the master regulator Xiap, down-regulation of which has been shown to sensitize PDA to gemcitabine. Decreases in XIAP protein by FG-3019 in the presence and absence of gemcitabine were confirmed by immunoblot, while increases in XIAP protein were seen in PDA cell lines treated with recombinant CTGF. Therefore, alterations in survival cues following targeting of tumor microenvironmental factors may play an important role in treatment responses in animal models and, by extension, PDA patients.

ORGANISM(S): Mus musculus

PROVIDER: GSE46203 | GEO | 2013/06/24

SECONDARY ACCESSION(S): PRJNA198031

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-06-24 | E-GEOD-46203 | biostudies-arrayexpress
2011-07-10 | E-TABM-1153 | biostudies-arrayexpress
2022-04-01 | GSE171232 | GEO
2015-11-20 | E-GEOD-68857 | biostudies-arrayexpress
2015-11-20 | GSE68857 | GEO
| PRJNA718835 | ENA
2011-09-08 | E-GEOD-16416 | biostudies-arrayexpress
2010-09-16 | GSE22096 | GEO
2023-12-31 | GSE138481 | GEO
2023-12-31 | GSE138477 | GEO